

Academic Platform versus Technology

Based Services: Competitors or Partners?

Introduction

Douwe D. Breimer, PhD
Professor of Pharmacology
Former Rector Magnificus & President Leiden University




Universiteit Leiden




Leiden University

Leiden City of Discoveries



Bio Science Park: Feiten en Cijfers





- 120 Hectare
- 50 Bedrijven / 2.300 werknemers
- 8 Kennis instituten / 2.900 werknemers
- LUMC / 5.000 werknemers
- Twee incubatoren:
 - Academic Business Centre
 - BioPartner Center Leiden

Programme Round Table



- 11.30 Douwe D. Breimer - Introduction
- 11.40 Thomas Hankemeier - The Netherlands
Metabolomics Consortium
- 11.55 François Bocquel - Phenopro
- 12.10 Max van Min - FlexGen
- 12.25 Round Table discussion with participation of the
audience
- 12.55 Douwe D Breimer - Closing remarks





The Netherlands in recent years

- Innovation Platform, chaired by the Prime Minister
- Public Private Partnerships (PPP's)
 - TIPharma
 - Center for Translational Molecular Medicine
 - Biomaterials Platform
- Financed:
 - 50% government
 - 25% industries
 - 25% universities



TI PHARMA

Jointly shaping the future of medicines



Background: FDA and EMEA call for PPPs in drug research, Dutch Innovation Platform points to life sciences as a promising sector

- ▶ International:
 - FDA paper: Innovation Stagnation
 - EMEA Road Map to 2010




EMEA Road Map to 2010

Milestones

EMEA OBJECTIVES

EMEA ACTIONS

- ▶ National:
 - Dutch Innovation Platform points to life sciences as a promising sector for valorisation



The Strategic Research Program of TI Pharma is based upon a matrix of Therapeutic Areas and Enabling Technologies

Enabling technologies \ Therapeutic areas	(Auto-)Immune Diseases	Cardio-vascular Diseases	Cancer	Infectious Diseases	Brain Diseases
Therapeutic Target Finding, Validation & Animal Models	<p>▶ Therapeutic Areas based on Priority Medicines (WHO)</p>				
Lead Selection and In-Silico Modeling					
Predictive Drug Disposition and Toxicology	<p>▶ Enabling Technologies are relevant to research across the Therapeutic Areas</p>		<p>Special overall Research Platform: Drug Discovery, Development and Utilization</p> <ul style="list-style-type: none"> • Efficiency improvement • Early regulatory input 		
Biomarkers and Bio-sensing					
Drug Formulation, Delivery and Targeting					
Pharmaceutical Prod. Technologies					



TI Pharma (drugs) is closely collaborating with two other public private partnerships: CTMM (diagnosis) and BMM (devices)

CTMM: *diagnosis*

- ▶ Early detection of disease by in-vitro and in-vivo diagnostics
- ▶ Stratification of patients for personalized treatment
- ▶ Assessing efficiency and efficacy of medicines by imaging
- ▶ Image guided delivery of medication
- ▶ Focus on cardiovascular disease and cancer

Center
for Translational
Molecular
Medicine

Biomarkers

Image guided drug delivery



*Imaging for
regenerative
medicine*

*Drug
delivery*

BMM: *devices*

- ▶ Smart drug delivery systems
- ▶ Innovations in contemporary organ replacement therapies
- ▶ Passive and active scaffolds, including cell signalling functions

TI Pharma: *drugs*

- ▶ Translational research on novel pharmaceutical therapies
- ▶ Target finding, animal models and lead selection
- ▶ Validation of biomarkers and bio-sensing
- ▶ Drug formulation, delivery and targeting
- ▶ Special Theme focusing on the efficiency of the process of drug development



The Netherlands pursues a three pillar 'Build – Bundle – Benefit' strategy

Different initiatives in the three pillar strategy of the Dutch Life Science & Health sector

